Drug Profile
AB 403021
Alternative Names: AB-4030-21; AB-4030-21/YBYSLatest Information Update: 15 Oct 2021
Price :
$50
*
At a glance
- Originator AlphaBeta Pharma
- Developer AlphaBeta Pharma; Unknown
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Viral infections
Most Recent Events
- 15 Oct 2021 No development reported - Phase-II for Bacterial infections in United Kingdom (unspecified route)
- 15 Oct 2021 No development reported - Phase-II for Viral infections in United Kingdom (unspecified route)
- 17 Jan 2018 Phase-II development in Bacterial infections is ongoing in United Kingdom (AlphaBeta Pharma pipeline, January 2018)